|  | CV-events (0 vs. ≥1) | Admissions (0 vs. ≥1) | IDH-episodes (0 vs. ≥1) | TnT-peaks (0 vs. ≥1) |
---|---|---|---|---|---|
 | n | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
Baseline TnT | |||||
 log (TnT) | 81 | 2.25 (1.04–4.86) | 2.62 (1.22–5.64) | 1.87 (0.98–3.59) | 0.94 (0.52–1.71) |
 Low (TnT ≤ 45 ng/L) vs. High (TnT > 45 ng/L) | 81 | 1.72 (0.58–5.09) | 3.74 (1.29–10.86) | 2.68 (1.05–6.79) | 0.84 (0.35–2.03) |
TnT change (Δ = 12 months-baseline) | |||||
 Δlog (TnT) | 54 | 1.17 (0.20–6.93) | 0.64 (0.14–2.91) | 0.26 (0.04–1.56) | – |
 Increase (ΔTnT> 0) vs. Decrease (ΔTnT≤0) | 54 | 0.76 (0.19–3.01) | 0.30 (0.08–1.10) | 0.31 (0.10–0.96) | – |
TnT amplitude (max-min) | |||||
 Low (TnT ≤ 20.5 ng/L) vs. High (TnT > 20.5 ng/L) | 54 | 0.61 (0.15–2.46) | 4.60 (1.24–16.97) | 3.08 (0.97–9.67) | – |
TnT-Peaks | |||||
 No peak vs. ≥1 peak | 81 | 1.05 (0.51–2.15) | 2.30 (1.00–5.30) | 1.33 (0.73–2.44) | – |
 Asprin (n = 37) vs. non-aspirin treatment (n = 44) | 81 | 1.96 (0.66–5.80) | 0.54 (0.20–1.44) | 0.69 (0.28–1.73) | 0.28 (0.11–0.72) |